FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2421926648> ?p ?o ?g. }

• W2421926648 startingPage "486" @default.
• W2421926648 abstract "BACKGROUND The goal of this study is to assess the 24-week efficacy of the addition of rosiglitazone 4 mg to existing full dose sulfonylurea (SU) and metformin (MET) therapy in patients with inadequately controlled type 2 diabetes, and to observe the continued follow-up efficacy and safety of this drug for up to two years. METHODS This study consists of 32 patients. Fasting plasma glucose (FPG), free fatty acid (FFA), high sensitive C-reactive protein (HS-CRP), adiponectin, insulin and C-peptide were measured every four weeks up to week 24. After that time, the FPG continued to be checked every month. Glycated hemoglobin (HbA1c) and lipid profiles were also checked every 12 weeks for more than two years. RESULTS HbA1c was reduced by 1.4% at week 12 and by 1.1% at week 24. However HbA1c was still above 9% throughout the whole study period. FPG was reduced significantly when comparing the baseline value to the value after treatment. The FPG values after one year and two years follow-up were similar to the value at week 24. The serum total cholesterol and low density lipoprotein (LDL) cholesterol levels increased significantly. Serum triglycerides were reduced significantly. Significant reductions in serum FFA from baseline to week 24 were observed. A gradually decrease of serum HS-CRP was noted from baseline to week 24. Serum adiponectin levels increased maximally at week 12 and then it decreased gradually, showing a significant change. Serum insulin and C-peptide levels showed significant changes from baseline to week 24. There were no acute cardiocerebral peripheral vascular disease events or liver damage within the entire study period. CONCLUSIONS Clinical improvement in glycemic control was observed after the addition of rosiglitazone to type 2 diabetic patients receiving full dose SU and MET therapy. The maximal effect was observed at week 12 and the effect continued for at least two years. Further, the combination therapy also resulted in an improvement in lipid profiles, decreased HS-CRP and increased adiponectin levels in the short term (24 weeks). This combination therapy is also safe and beneficial for at least two years because no acute episodes of cardiocerebral peripheral vascular disease were seen." @default.
• W2421926648 created "2016-06-24" @default.
• W2421926648 creator A5004969981 @default.
• W2421926648 creator A5046218320 @default.
• W2421926648 creator A5056152507 @default.
• W2421926648 creator A5071120720 @default.
• W2421926648 creator A5075286023 @default.
• W2421926648 creator A5077405135 @default.
• W2421926648 creator A5090533903 @default.
• W2421926648 creator A5090857642 @default.
• W2421926648 date "2006-09-01" @default.
• W2421926648 modified "2023-09-23" @default.
• W2421926648 title "Two-year effect of rosiglitazone in chinese poorly controlled type 2 diabetic patients." @default.
• W2421926648 cites W1556459089 @default.
• W2421926648 cites W1968237817 @default.
• W2421926648 cites W1969927159 @default.
• W2421926648 cites W1973725028 @default.
• W2421926648 cites W1981261500 @default.
• W2421926648 cites W1982990554 @default.
• W2421926648 cites W1983046008 @default.
• W2421926648 cites W2003323316 @default.
• W2421926648 cites W2015279471 @default.
• W2421926648 cites W2020468088 @default.
• W2421926648 cites W2043566560 @default.
• W2421926648 cites W2048529677 @default.
• W2421926648 cites W2062560800 @default.
• W2421926648 cites W2065569245 @default.
• W2421926648 cites W2077760013 @default.
• W2421926648 cites W2094083143 @default.
• W2421926648 cites W2098859779 @default.
• W2421926648 cites W2100514340 @default.
• W2421926648 cites W2108931588 @default.
• W2421926648 cites W2111184067 @default.
• W2421926648 cites W2131702141 @default.
• W2421926648 cites W2132681327 @default.
• W2421926648 cites W2140603676 @default.
• W2421926648 cites W2151025367 @default.
• W2421926648 cites W2152316341 @default.
• W2421926648 cites W2160234571 @default.
• W2421926648 cites W2164367541 @default.
• W2421926648 cites W2169005776 @default.
• W2421926648 cites W3209867873 @default.
• W2421926648 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17214393" @default.
• W2421926648 hasPublicationYear "2006" @default.
• W2421926648 type Work @default.
• W2421926648 sameAs 2421926648 @default.
• W2421926648 citedByCount "0" @default.
• W2421926648 crossrefType "journal-article" @default.
• W2421926648 hasAuthorship W2421926648A5004969981 @default.
• W2421926648 hasAuthorship W2421926648A5046218320 @default.
• W2421926648 hasAuthorship W2421926648A5056152507 @default.
• W2421926648 hasAuthorship W2421926648A5071120720 @default.
• W2421926648 hasAuthorship W2421926648A5075286023 @default.
• W2421926648 hasAuthorship W2421926648A5077405135 @default.
• W2421926648 hasAuthorship W2421926648A5090533903 @default.
• W2421926648 hasAuthorship W2421926648A5090857642 @default.
• W2421926648 hasConcept C126322002 @default.
• W2421926648 hasConcept C134018914 @default.
• W2421926648 hasConcept C2776782570 @default.
• W2421926648 hasConcept C2777180221 @default.
• W2421926648 hasConcept C2777391703 @default.
• W2421926648 hasConcept C2777538456 @default.
• W2421926648 hasConcept C2778163477 @default.
• W2421926648 hasConcept C2778270857 @default.
• W2421926648 hasConcept C2778854520 @default.
• W2421926648 hasConcept C2778917026 @default.
• W2421926648 hasConcept C2779306644 @default.
• W2421926648 hasConcept C2780152017 @default.
• W2421926648 hasConcept C2780323712 @default.
• W2421926648 hasConcept C555293320 @default.
• W2421926648 hasConcept C71924100 @default.
• W2421926648 hasConceptScore W2421926648C126322002 @default.
• W2421926648 hasConceptScore W2421926648C134018914 @default.
• W2421926648 hasConceptScore W2421926648C2776782570 @default.
• W2421926648 hasConceptScore W2421926648C2777180221 @default.
• W2421926648 hasConceptScore W2421926648C2777391703 @default.
• W2421926648 hasConceptScore W2421926648C2777538456 @default.
• W2421926648 hasConceptScore W2421926648C2778163477 @default.
• W2421926648 hasConceptScore W2421926648C2778270857 @default.
• W2421926648 hasConceptScore W2421926648C2778854520 @default.
• W2421926648 hasConceptScore W2421926648C2778917026 @default.
• W2421926648 hasConceptScore W2421926648C2779306644 @default.
• W2421926648 hasConceptScore W2421926648C2780152017 @default.
• W2421926648 hasConceptScore W2421926648C2780323712 @default.
• W2421926648 hasConceptScore W2421926648C555293320 @default.
• W2421926648 hasConceptScore W2421926648C71924100 @default.
• W2421926648 hasIssue "5" @default.
• W2421926648 hasLocation W24219266481 @default.
• W2421926648 hasLocation W24219266482 @default.
• W2421926648 hasOpenAccess W2421926648 @default.
• W2421926648 hasPrimaryLocation W24219266481 @default.
• W2421926648 hasRelatedWork W1502396064 @default.
• W2421926648 hasRelatedWork W1971657088 @default.
• W2421926648 hasRelatedWork W2018106703 @default.
• W2421926648 hasRelatedWork W2171519044 @default.
• W2421926648 hasRelatedWork W2188180356 @default.
• W2421926648 hasRelatedWork W2347284929 @default.
• W2421926648 hasRelatedWork W2359001529 @default.
• W2421926648 hasRelatedWork W2369763536 @default.

• next